Atp4b-IRES-CreERT2

Nomenclature

C57BL/6Smoc-Atp4bem1(IRES-CreERT2-WPRE-pA)Smoc

Cat. NO.

NM-KI-210118

Strain State

Sperm cryopreservation

Export PDF

Gene Summary

Gene Symbol
Atp4b

Synonyms

AV080843

NCBI ID

11945

MGI ID

88114

Ensembl ID

ENSMUSG00000031449

Pubmed

Atp4b

Human Ortholog

ATP4B

Model Description

An IRES-CreERT2-WPRE-pA expression cassette was knocked into the Atp4b gene stop codon site. Besides, An IRES-CreERT2 expression cassette were knock into the Bhlha15 gene stop codon site to generate Atp4b-IRES-CreERT2(2)(Stock No. NM-KI-210119) mice.
Research Application：Cre tool mice

Validation Data

image.png

Fig1. CreERT2-mediated recombination in the stomach of Atp4bCreERT2/+; Rosa26tdTomato/+ mouse. TdTomato(red) expression can be detected in the stomach of Atp4bCreERT2/+; Rosa26tdTomato/+ mouse after tamoxifen treatment. Some leakiness was detected prior to tamoxifen exposure.

image.png

image.png

Fig2. Detection of tdTomato (red) in various tissues of  Atp4bCreERT2/+; Rosa26tdTomato/+ mice after tamoxifen treatment. Tdtomato was expressed in the glandular stomach. Tdtomato can also be detected in the pituitary, thymus, salivary glands, brown adipose tissue, spleen, pancreas, and muscle. Some leakiness was detected prior to tamoxifen exposure. TdTomato expression can not be detected in the brain, liver, lung, large intestine, small intestine, kidney or skin.

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more